Cargando…

A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer

OBJECTIVE: Androgen deprivation therapy (ADT) reduces muscle and bone mass, increasing frailty in men with prostate cancer. The liver mediates the whole body anabolic effects of testosterone. Based on first-pass metabolism, liver-targeted testosterone treatment (LTTT) entails oral delivery of a smal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhee, Handoo, Navaratnam, Anojan, Oleinikova, Irina, Gilroy, Deborah, Scuderi, Yolanda, Heathcote, Peter, Nguyen, Tuan, Wood, Simon, Ho, Ken K Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294688/ https://www.ncbi.nlm.nih.gov/pubmed/34308090 http://dx.doi.org/10.1210/jendso/bvab116

Ejemplares similares

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
por: Cabarkapa, Sonja, et al.
Publicado: (2018)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
por: Nam, Wook, et al.
Publicado: (2018)

Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
por: Korczak, Jolanta, et al.
Publicado: (2023)

Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
por: Borque-Fernando, Ángel, et al.
Publicado: (2023)

Testosterone and Sarcopenia
por: Shin, Myung Jun, et al.
Publicado: (2018)

Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling()
por: Zaslavsky, Alexander B., et al.
Publicado: (2015)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Partial Androgen Deficiency, Depression, and Testosterone Supplementation in Aging Men
por: Amore, Mario, et al.
Publicado: (2012)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone
por: Salciccia, Stefano, et al.
Publicado: (2020)

Relationship between Testosterone and Sarcopenia in Older-Adult Men: A Narrative Review
por: Shigehara, Kazuyoshi, et al.
Publicado: (2022)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
por: Jayadevappa, Ravishankar, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer
por: Kanazawa, Kazo, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
por: Bang, Woo Jin, et al.
Publicado: (2022)

Updates in Urologic Robot Assisted Surgery
por: Navaratnam, Anojan, et al.
Publicado: (2018)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania
por: Drevinskaite, Mingaile, et al.
Publicado: (2021)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
por: Shim, Myungsun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h1n5akbrre7qkf10qfeuugmp04